Your session is about to expire
← Back to Search
Disulfiram for Multiple Myeloma (Repurpose-1 Trial)
Repurpose-1 Trial Summary
This trial is testing a new combination of drugs to treat patients with multiple myeloma who have not responded to other treatments. The goal is to find the best dose of the combination, assess its safety and tolerability, and expand the cohort to further characterize the combination.
- Multiple Myeloma
Repurpose-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Repurpose-1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any vacancies currently available for this clinical trial?
"The data published on clinicaltrials.gov indicates that this medical investigation is recruiting patients now - the trial was first posted in May 2021 and recently updated in March 2022."
How many participants are currently partaking in this clinical investigation?
"Affirmative, clinicaltrials.gov data shows that this research is currently looking for participants. Since it was first posted on May 21st 2021 and last amended on March 1st 2022, 38 patients are needed to take part in the trial at a single location."
What potential harms could patients suffer from Disulfiram consumption?
"Our assessment at Power of Disulfiram's safety is rated as a 1, due to the fact that this trial is in Phase One and there are only limited amounts of clinical data highlighting its efficacy."
Share this study with friends
Copy Link
Messenger